Tropical Weight Loss
Tropical Weight Loss
Photo: Any Lane
The two molecules do not act in precisely the same way: Wegovy is a GLP-1 analogue whereas tirzepatide is a GIP/GLP-1 agonist. Both are prone to gastrointestinal side-effects.
In conclusion, the 14-day boiled egg diet can help to trim off unwanted pounds, it is easy to follow, and it includes simple and healthy foods....
Read More »
To lose 10 pounds in 3 days would mean decreasing your calorie intake by 35,000 calories in just 3 days! The Academy of Nutrition and Dietetics...
Read More »The data from the first and largest of Lilly’s pivotal trials of tirzepatide in obesity are in, and the GIP/GLP-1 agonist has smashed the target set by Novo’s Wegovy. Patients given the highest dose in the Surmount-1 study lost more than 20% of their body weight, a result that beat many expectations. Importantly, tolerability also looks competitive to Wegovy and in line with hopes, with Lilly also highlighting low discontinuation rates. Describing the data as “at the top end of what we thought possible”, the company’s chief medical officer Dan Skovronsky said talks will now be sought with regulators about filing on this first trial alone. Previously, Lilly had agreed with the FDA that a filing would be made once the Surmount programme had completed reading out; the three remaining trials are due to yield data in mid-2023. Should the agency agree to review the drug sooner, Lilly’s attempts to grab share of the burgeoning obesity market from Novo would be given a major boost. Mr Skovronsky declined to say whether a recently acquired priority review voucher would be used to speed any submission, but given Lilly's huge investment in this asset, tirzepatide would be presumably be a prime candidate for such a move. “To be clear, we are not announcing an early filing – we are just discussing the next steps” with regulators, Mr Skovronsky told analysts on Lilly’s first-quarter earnings call today. “But given the huge market need, we think it warrants trying to find a path to accelerate [tirzepatide] to market.” The data and the potential for a quicker launch was enough to send Lilly shares up 2% in early trade; Novo Nordisk sank 2.5%. Mike Mason, head of diabetes for Lilly, cautioned that should tirzepatide reach the market “it won’t sprint out of the gate”. While there is considerable long-term potential, demand is likely to build slowly, he said. Poor reimbursement has long been an issue for obesity drugs, although Mr Mason said that is improving, thanks to the significantly better data being generated with tirzepatide and Wegovy versus results seen with older options. “Former agents were more cosmetic than offering real health benefits. The [reimbursement] trends are moving towards better access,” he said, adding that if Lilly can show tirzepatide can help improve related conditions like sleep apnoea, the gates could open even more easily.
Clear urine indicates that you're drinking more than the daily recommended amount of water. While being hydrated is a good thing, drinking too much...
Read More »
Regular consumption of an egg-based breakfast has also been associated with increased weight loss over time ( 17 ). According to one study...
Read More »
13 Foods That Help Your Body Produce Collagen To supplement or to eat? “Diet plays a surprisingly large role in the appearance and youthfulness of...
Read More »
Details 5'5"–5'9" (165–175 cm) tall, average bust, average back Dimension/size 4 10 Bust 32-34 36½ Waist 22-24½ 29 Hip 33-35½ 39 1 more row
Read More »
Physical activity: Walking, chasing after your kids, playing tennis and other forms of exercise cause your body to burn more calories than being...
Read More »
Important nutrients for hair growth B vitamins. Deficiencies in riboflavin, biotin, folate, and vitamin B12 have been associated with hair loss ( 2...
Read More »
Promotion
Promotion
Promotion
Promotion